CRO report identifies trends and opportunities in the life science sector

May 11, 2015 Guest Contributor

 

Guest post by Natalie Morrison, Senior Reporter at BioPharm Insight

BioPharm Insight’s (BPI) 1Q15 CRO report, compiled by analyst Peter Murphy, delves into trends and opportunities in the life sciences services sector.

The report notes oncology was the most trialed indication, totaling 20% of all human studies initiated in 1Q15. More notably, CNS trial launches rose from 12% to 15%, indicative of big pharma’s growing interest in the field.  

Only two of the five most active CRO-sponsor relationships have multi-trial contracts, reflective of waning sponsor interest in strategic CRO partnerships.

In Asia Pacific, new trial launches dropped from 1,173 to 674 year-on-year. A particularly drastic decline in China was noted, potentially due to sluggish regulatory processes. In spite of this, Asia-Pac M&A remains strong for bigger CROs such as Clinipace, whose CEO earmarked Asia in its M&A strategy.

Please click here for the 1Q15 CRO report. To request a free trial with BPI, please click here.

 

 

Previous Article
Lysosomal Therapeutics:  Brilliant science, brilliant networks
Lysosomal Therapeutics: Brilliant science, brilliant networks

A cure for Parkinson’s disease may be possible if the research at Lysosomal Therapeutics, Inc. (LIT) advanc...

Next Article
Help us reach our 30,000 members milestone and you could be a winner!
Help us reach our 30,000 members milestone and you could be a winner!

partnering360®, your life science dealmaker network, is about to celebrate a milestone. We are nearing our ...